DENTSPLY SIRONA Inc. (XRAY) AI Stock Analysis
XRAY AI stock analysis summary
AI ResearchDENTSPLY SIRONA Inc. manufactures and distributes dental equipment and consumables for the professional dental market worldwide. Trailing twelve month revenue reached $3.64B with a profit margin of -15.0% and an operating margin of 9.2%. The stock closed at $8.57, down 31.1% over the past year.
- Market cap
- $1.71B
- Revenue (TTM)
- $3.64B
- P/E
- — fwd 6.3x
- 1Y return
- -31.1% S&P 500 16.8%
- Avg. target
- $12.67 47.8% vs last close
Bull case
- The analyst mean price target of $12.67 represents a 47.8% upside relative to the closing price of $8.57.
- The stock trades at a forward P/E of 6.3x and a price-to-sales ratio of 0.5x, well below the US-listed Healthcare peer medians of 17.3x and 4.1x.
- Quarterly earnings grew 15.2% year-over-year in the latest quarter ended June 30, 2026.
Bear case
- The company reported net income of -$598.0M in FY2025 and -$910.0M in FY2024, continuing a streak of annual net losses.
- Total debt of $2.31B exceeds cash and short-term investments of $239.0M, leaving net debt at $2.07B and a debt-to-equity ratio of 1.71.
- The stock price fell 83.5% over the past five years and dropped 31.1% over the past twelve months.
What DENTSPLY SIRONA does
Headquartered in Charlotte, North Carolina, DENTSPLY SIRONA Inc. manufactures and distributes dental products and technologies for the professional dental market. The company operates through two primary segments: Technologies & Equipment and Consumables. The Technologies & Equipment segment provides dental practitioners with treatment centers, imaging devices, motorized handpieces, CAD/CAM digital dental workflow tools, and clear aligners such as SureSmile. The Consumables segment supplies endodontic tools, dental ceramics, artificial teeth, intraoral curing lights, ultrasonic scalers, dental anesthetics, impression materials, teeth whiteners, and fluoride treatments.
Growth and profitability
Annual revenue declined from $4.23B in FY2021 to $3.92B in FY2022, rose to $3.96B in FY2023, and fell to $3.79B in FY2024 and $3.68B in FY2025. Net income was $411.0M in FY2021 before recording net income of -$950.0M in FY2022, -$132.0M in FY2023, -$910.0M in FY2024, and -$598.0M in FY2025. Gross margin compressed from 55.5% in FY2021 to 50.0% in FY2025. For the trailing twelve months, revenue reached $3.64B with an operating margin of 9.2%. In the latest quarter ended June 30, 2026, quarterly revenue fell 4.1% year-over-year, while quarterly earnings grew 15.2%.
Balance sheet and cash flow
As of June 30, 2026, DENTSPLY SIRONA held $239.0M in cash and short-term investments against total debt of $2.31B, resulting in net debt of $2.07B. Shareholders' equity was $1.35B and total assets stood at $5.20B. The company recorded a current ratio of 1.63 and a debt-to-equity ratio of 1.71. For FY2025, operating cash flow was $235.0M and free cash flow was $104.0M, while capital expenditures were $131.0M and dividends paid totaled $128.0M. The company reduced its share count 8.5% over five years.
Valuation and performance
DENTSPLY SIRONA trades at a forward P/E of 6.3x, below the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales ratio is 0.5x compared to the peer median of 4.1x, while its EV-to-EBITDA stands at 43.3x versus the peer median of 12.0x. The enterprise value is $4.02B against a market cap of $1.71B. Over the past year, the stock fell 31.1%, trailing the S&P 500 return of 16.8%. Over five years, the stock fell 83.5%, compared to an 83.0% gain for the S&P 500.
What analysts expect
Analyst coverage consists of 2 Strong Buy, 2 Buy, 12 Hold, and 1 Sell ratings. The mean price target is $12.67, representing a 47.8% premium over the last close of $8.57. For the current fiscal year ending December 31, 2026, consensus estimates project EPS of $1.49 on revenue of $3.57B. For the next fiscal year, 17 analysts project EPS of $1.50 and revenue of $3.62B. The company beat EPS estimates in 1 of the last 4 quarters. The next earnings date is November 5, 2026.
Key risks and what to watch
- Free cash flow fell from $515.0M in FY2021 to $104.0M in FY2025, which may constrain internal funding capacity.
- Short interest represents 14.3% of the public float.
- Quarterly revenue fell 4.1% year-over-year in the quarter ended June 30, 2026, following annual revenue drops in FY2024 and FY2025.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this XRAY AI stock analysis
This page is an AI-written research summary of DENTSPLY SIRONA Inc. (XRAY). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: XRAY income statement, XRAY balance sheet, XRAY key metrics, XRAY analyst forecast, XRAY chart. See the XRAY stock overview for the latest quote and news.
XRAY AI stock analysis FAQ
What is DENTSPLY SIRONA's market capitalization?
As of October 16, 2026, DENTSPLY SIRONA has a market cap of $1.71B and an enterprise value of $4.02B.
When does DENTSPLY SIRONA report its next quarterly earnings?
The company's next earnings announcement is scheduled for November 5, 2026.
How much debt does DENTSPLY SIRONA carry?
As of June 30, 2026, the company had $2.31B in total debt and $239.0M in cash and short-term investments, resulting in net debt of $2.07B.
What are analysts forecasting for XRAY?
Analysts maintain a mean price target of $12.67 across 17 ratings. For the fiscal year ending December 31, 2026, estimated revenue is $3.57B and projected EPS is $1.49.